Clinical trials: Malignant Neoplasm of Colon
Colon Cancer, Rectal Cancer
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
The purpose of this study is to determine if participants with metastatic colorectal cancer live longer without their cancer progressing when treated with standard chemotherapy, standard chemotherapy plus ramucirumab, or standard…
- Trial name
- NCT01111604
- Testing
- Ramucirumab, Icrucumab, mFOLFOX-6
- Where
- 17 sites in United States, Canada
- Volunteers
- 158 people
- Sponsor
- Eli Lilly and Company
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Breast Cancer
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with other anticancer agents in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumor, Breast Cancer, Colon Cancer, Cholangiocarcinoma
- Trial name
- NCT02784795
- Testing
- LY3039478, Taladegib, Abemaciclib
- Where
- 11 sites in United States, Denmark and 2 more
- Volunteers
- 94 people
- Sponsor
- Eli Lilly and Company
Colorectal Carcinoma, Liver Metastases
FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma
This pilot study will evaluate the safety and effectiveness of chemo-radiotherapy comprising a regimen of FOLFOX6 chemotherapy plus SIR-Spheres yttrium-90 microspheres (chemo-radiotherapy, also known as "chemo-SIRT"), in…
- Trial name
- FAST (NCT00735241)
- Testing
- SIR-Spheres microspheres, FOLFOX6 cycles 1-3, FOLFOX6 cycles 4 onwards
- Where
- 3 sites in United States
- Sponsor
- Sirtex Medical
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Carcinoma
A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer
The main purpose of this observational study with Oxaliplatin onkovis is to determine the number of treatment cycles and the quantity of Oxaliplatin onkovis needed for this purpose under the special circumstances of ambulant…
- Trial name
- NCT01942200
- Where
- 3 sites in Germany
- Volunteers
- 383 people
- Sponsor
- Onkovis GmbH
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Colorectal Neoplasms, Colorectal Cancer
Microbiome Test for the Detection of Colorectal Polyps and Cancer
The purpose if this study is to measure the sensitivity, specificity and accuracy of the Metabiomics Colon Polyp and Colorectal Cancer Assay for the non-invasive detection of colon polyps or colorectal cancer.
- Trial name
- NCT02141945
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Metabiomics Corp
Colon Cancer, Rectal Cancer
A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).
- Trial name
- FC-4 (NCT00845039)
- Testing
- Cetuximab, Irinotecan, IMC-A12 (cixutumumab)
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Colorectal Neoplasms
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
The main objectives of this study are to establish a safe, tolerable and active dose of 1018 ISS administered in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer.
- Trial name
- NCT00403052
- Testing
- 1018 ISS immunostimulatory oligonucleotide
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Dynavax Technologies Corporation
Gastric Cancer, Colon Cancer
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer
- Trial name
- NCT06126406
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Colorectal Cancer, Liver Neoplasms
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus…
- Trial name
- NCT00149396
- Testing
- NV1020
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- MediGene
Advanced Solid Tumors
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and…
- Trial name
- NCT01302405
- Testing
- PRI-724
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Prism Pharma Co., Ltd.
Breast Cancer, Colon Cancer
EXoPERT EMERALD Clinical Study
The purpose of this study is to establish a multi-center clinical repository of blood samples to support the development and evaluation of an artificial intelligence-based in vitro diagnostic software.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- NCT07186296
- Testing
- EXoPred
- Where
- 9 sites in United States
- Volunteers
- 1,400 people, healthy volunteers welcome
- Sponsor
- EXoPERT
Lung Cancer, Colon Cancer
A Study of PHN-010 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
- Conditions
- Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT06457997
- Testing
- PHN-010
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Pheon Therapeutics
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx